These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

621 related articles for article (PubMed ID: 21471425)

  • 1. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine.
    Cheever MA; Higano CS
    Clin Cancer Res; 2011 Jun; 17(11):3520-6. PubMed ID: 21471425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.
    Sims RB
    Vaccine; 2012 Jun; 30(29):4394-7. PubMed ID: 22122856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
    Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer.
    Thara E; Dorff TB; Pinski JK; Quinn DI
    Maturitas; 2011 Aug; 69(4):296-303. PubMed ID: 21621934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.
    Di Lorenzo G; Ferro M; Buonerba C
    BJU Int; 2012 Jul; 110(2 Pt 2):E99-104. PubMed ID: 22177289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sipuleucel-T (APC8015) for prostate cancer.
    So-Rosillo R; Small EJ
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1163-7. PubMed ID: 17020451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.
    Shore ND; Mantz CA; Dosoretz DE; Fernandez E; Myslicki FA; McCoy C; Finkelstein SE; Fishman MN
    Cancer Control; 2013 Jan; 20(1):7-16. PubMed ID: 23302902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer.
    Patel PH; Kockler DR
    Ann Pharmacother; 2008 Jan; 42(1):91-8. PubMed ID: 18094343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sipuleucel-T (Provenge(®))-Autopsy of an Innovative Paradigm Change in Cancer Treatment: Why a Single-Product Biotech Company Failed to Capitalize on its Breakthrough Invention.
    Jarosławski S; Toumi M
    BioDrugs; 2015 Oct; 29(5):301-7. PubMed ID: 26403092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer.
    McKarney I
    Issues Emerg Health Technol; 2007 Sep; (101):1-4. PubMed ID: 17763575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sipuleucel-T: a therapeutic cancer vaccine for the treatment of castration- or hormone-refractory prostate cancer.
    Bulloch MN; Elayan MM; Renfroe HR
    Expert Rev Clin Pharmacol; 2011 Nov; 4(6):685-92. PubMed ID: 22111853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions.
    Wei XX; Fong L; Small EJ
    Expert Rev Vaccines; 2015; 14(12):1529-41. PubMed ID: 26488270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine.
    Wargowski E; Johnson LE; Eickhoff JC; Delmastro L; Staab MJ; Liu G; McNeel DG
    J Immunother Cancer; 2018 Mar; 6(1):21. PubMed ID: 29534736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cell-based immunotherapy for prostate cancer.
    Jähnisch H; Füssel S; Kiessling A; Wehner R; Zastrow S; Bachmann M; Rieber EP; Wirth MP; Schmitz M
    Clin Dev Immunol; 2010; 2010():517493. PubMed ID: 21076523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sipuleucel-T for prostate cancer: the immunotherapy era has commenced.
    Buonerba C; Ferro M; Di Lorenzo G
    Expert Rev Anticancer Ther; 2011 Jan; 11(1):25-8. PubMed ID: 21166508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for castration-resistant prostate cancer.
    Sonpavde G; Kantoff PW
    Urol Clin North Am; 2012 Nov; 39(4):465-81. PubMed ID: 23084524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sipuleucel-T for the treatment of advanced prostate cancer.
    Frohlich MW
    Semin Oncol; 2012 Jun; 39(3):245-52. PubMed ID: 22595047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.
    Huber ML; Haynes L; Parker C; Iversen P
    J Natl Cancer Inst; 2012 Feb; 104(4):273-9. PubMed ID: 22232132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm.
    Garcia JA; Dreicer R
    Oncology (Williston Park); 2011 Mar; 25(3):242-9. PubMed ID: 21548467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.
    Rini BI; Weinberg V; Fong L; Conry S; Hershberg RM; Small EJ
    Cancer; 2006 Jul; 107(1):67-74. PubMed ID: 16736512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.